Phase III ASCENT Study of Metastatic TNBC Halted Due to Compelling Efficacy
The decision to halt the study was based on the unanimous recommendation by an independent data safety monitoring committee during its routine review of the ASCENT study.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
More News: Cancer & Oncology | Study